Linked Life Data

18519919

Source:http://linkedlifedata.com/resource/pubmed/id/18519919

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18519919rdf:typepubmed:Citationlld:pubmed
pubmed-article:18519919lifeskim:mentionsumls-concept:C0042960lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C0024554lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C1549078lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C1997894lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C0851347lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C1097411lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C0175727lld:lifeskim
pubmed-article:18519919lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18519919pubmed:issue8lld:pubmed
pubmed-article:18519919pubmed:dateCreated2008-7-24lld:pubmed
pubmed-article:18519919pubmed:abstractTextThe aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension. Fifty-eight healthy male volunteers received a single oral dose of BAY 63-2521 (0.25-5 mg) or placebo. No serious adverse events were reported; there were no life-threatening events. Heart rate over 1 minute, an indicator of the effect of a vasodilating agent on the cardiovascular system in healthy subjects, was increased dose dependently versus placebo at BAY 63-2521 doses of 1 to 5 mg (P < .01). Mean arterial and diastolic pressures were decreased versus placebo at doses of 1 mg (P < .05) and 5 mg (P < .01). Systolic pressure was not significantly affected. BAY 63-2521 was readily absorbed and exhibited dose-proportional pharmacokinetics. The pharmacodynamic and pharmacokinetic properties of BAY 63-2521 suggest that it can offer a unique mode of action in the treatment of pulmonary hypertension.lld:pubmed
pubmed-article:18519919pubmed:languageenglld:pubmed
pubmed-article:18519919pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:citationSubsetIMlld:pubmed
pubmed-article:18519919pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18519919pubmed:statusMEDLINElld:pubmed
pubmed-article:18519919pubmed:monthAuglld:pubmed
pubmed-article:18519919pubmed:issn0091-2700lld:pubmed
pubmed-article:18519919pubmed:authorpubmed-author:WensingGeorgGlld:pubmed
pubmed-article:18519919pubmed:authorpubmed-author:UngerSigrunSlld:pubmed
pubmed-article:18519919pubmed:authorpubmed-author:FreyReinerRlld:pubmed
pubmed-article:18519919pubmed:authorpubmed-author:MückWolfgangWlld:pubmed
pubmed-article:18519919pubmed:authorpubmed-author:Artmeier-Bran...lld:pubmed
pubmed-article:18519919pubmed:authorpubmed-author:WeimannGerrit...lld:pubmed
pubmed-article:18519919pubmed:issnTypePrintlld:pubmed
pubmed-article:18519919pubmed:volume48lld:pubmed
pubmed-article:18519919pubmed:ownerNLMlld:pubmed
pubmed-article:18519919pubmed:authorsCompleteYlld:pubmed
pubmed-article:18519919pubmed:pagination926-34lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:meshHeadingpubmed-meshheading:18519919...lld:pubmed
pubmed-article:18519919pubmed:year2008lld:pubmed
pubmed-article:18519919pubmed:articleTitleSingle-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.lld:pubmed
pubmed-article:18519919pubmed:affiliationClinical Pharmacology, Bayer HealthCare AG, Pharma Research Centre, Aprather Weg 18a, 42096 Wuppertal, Germany. reiner.frey@bayerhealthcare.comlld:pubmed
pubmed-article:18519919pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18519919pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18519919pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18519919lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18519919lld:pubmed